Bioterrorism: A Billion-Plus for Countermeasures, But Also New Strings
This article was originally published in Start Up
The new US bioterrorism bill will direct hundreds of millions of dollars toward bolstering the US pharmaceutical stockpile. At the same time, it imposes reporting and other obligations on companies. On the other hand, some regulatory burdens on companies will be eased. And because FDA may now find now in an unusual dual position with respect to risk taking--promoting industry while at the same time regulating--it could create a different dynamic with companies.
You may also be interested in...
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.